Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

1,022.02 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Feb 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
OPKO Health (OPK) Q4 2025 Earnings Call Transcript ↗
OPKO Health (OPK) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
The Great Recalibration: Investors Pivot from Silicon Dreams to Industrial Reality
As the bull market of the mid-2020s enters a more mature and discerning phase, a profound shift is unfolding across global trading floors. The speculative fervor that once propelled "AI darlings" to... 
Via MarketMinute
Topics Artificial Intelligence Economy Fraud
News headline image
Forget Altimmune: This Proven Obesity‑Drug Giant Is the Better Weight‑Loss Play ↗
The maker of Wegovy hasn't said its last words just yet. 
Via The Motley Fool
News headline image
Why Shares of Novo Nordisk Stock Sank (Again) This Week ↗
The weight-loss drug innovator is falling behind in the industry and facing major pricing pressures. 
Via The Motley Fool
News headline image
Viking Therapeutics: The High-Stakes Weight Loss Contender ↗
Via MarketBeat
News headline image
Eli Lilly's New Oral Weight Loss Drug Outperforms Semaglutide, Eyes Potential US Approval In Q2 ↗
Eli Lilly shares rise after orforglipron beats Novo's drug in Phase 3, cutting A1C by 2.2% and boosting weight loss results. 
Via Benzinga
News headline image
The Darwinian Transition: AI Monetization and Metabolic Mastery Define the Market’s New Frontier
As the final week of February 2026 draws to a close, the financial markets have emerged from what analysts are calling the most consequential “Heavyweight Week” of the post-pandemic era. The... 
Via MarketMinute
Topics Artificial Intelligence Economy
News headline image
Pfizer Secures Full FDA Approval for BRAFTOVI in First-Line Colorectal Cancer, Bolstering Oncology Growth Strategy
In a move that solidifies a new standard of care for a high-risk patient population, the U.S. Food and Drug Administration (FDA) has granted full approval to Pfizer Inc. (NYSE: PFE) for its BRAFTOVI... 
Via MarketMinute
Topics Economy Intellectual Property
News headline image
Hims & Hers at the Crossroads: Navigating the ‘Regulatory Winter’ of 2026
As of February 26, 2026, Hims & Hers Health, Inc. (NYSE: HIMS) finds itself at the center of one of the most polarized debates in the modern healthcare sector. Once the "poster child" of the 2024-2025... 
Via Finterra
Topics Economy Initial Public Offering Intellectual Property
News headline image
Alphabet Inc. (GOOGL) Deep Dive: Navigating the Agentic Era and the $180 Billion AI Bet
As of February 26, 2026, Alphabet Inc. (NASDAQ: GOOGL) stands at a defining crossroads in its nearly three-decade history. Long the undisputed gatekeeper of the internet’s information, the Mountain... 
Via Finterra
Topics Artificial Intelligence Initial Public Offering Workforce
News headline image
Hims & Hers: The Telehealth Growth Story Younger Investors Can't Afford to Ignore ↗
How fast can Hims & Hers grow without selling GLP-1 drugs? Maybe a lot faster than you think. 
Via The Motley Fool
News headline image
Eli Lilly’s Diabetes Pill Outperforms Oral Semaglutide in Phase 3 Trial ↗
Investors are closely watching the oral GLP-1 race as competition intensifies across the sector. 
Via Stocktwits
News headline image
Earnings To Watch: Amneal (AMRX) Reports Q4 Results Tomorrow
Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) will be reporting results this Friday morning. Here’s what you need to know. 
Via StockStory
Topics Artificial Intelligence
News headline image
Stock Market Today, Feb. 25: Novo Nordisk Dips After Announcing $2.1 Billion Partnership With Vivtex for Oral Drug-Delivery Technologies ↗
Investors weigh steep GLP‑1 price cuts against a multibillion‑dollar oral obesity push, fresh analyst caution, and a new partnership, today, Feb. 25, 2026. 
Via The Motley Fool
Topics Stocks
News headline image
Eli Lilly Bolsters Genetic Medicine Portfolio with $2.4 Billion Acquisition of Orna Therapeutics
In a definitive move to dominate the next frontier of immunology and oncology, Eli Lilly and Company (NYSE: LLY) announced on February 9, 2026, its acquisition of Orna Therapeutics for a total... 
Via MarketMinute
Topics Intellectual Property
News headline image
Eli Lilly Just Took 2 Major Steps Forward in the Billion-Dollar Obesity Drug Market. Here's What You Need to Know. ↗
Eli Lilly has seen revenue and earnings soar in recent years. 
Via The Motley Fool
News headline image
Labor Resilience Defies 'Soft Landing' Narrative: ADP Pulse Data Shows Four Weeks of Growth, Forcing Fed Rethink
The U.S. labor market is flashing a surprising signal of late-cycle strength as the shortest month of the year comes to a close. Despite a lukewarm monthly headline in early February, the latest ADP... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
News headline image
1 Reason Why I'd Hold This Weight‑Loss Drug Leader Through Any Market Crash ↗
Although pegged as a weight-loss stock, this drug maker's core business has long been diabetes. 
Via The Motley Fool
Topics Economy
News headline image
Novo Nordisk's 40% Fall May Be Creating A Deep-Value Moment ↗
Novo Nordisk now trades at just 10.6x earnings after a 58% crash, far below Eli Lilly, Vertex, and Pfizer — signaling a valuation reset. 
Via Benzinga
News headline image
Amphastar Pharmaceuticals (AMPH) Reports Earnings Tomorrow: What To Expect
Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) will be reporting earnings tomorrow after market hours. Here’s what to expect. 
Via StockStory
Topics Artificial Intelligence
News headline image
Novo, Vivtex Ink $2.1 Billion Deal To Develop Oral Medicines For Obesity And Diabetes ↗
Novo Nordisk will lead global development, regulatory approval, manufacturing, and commercialization of the resulting products. 
Via Stocktwits
News headline image
Could Novo Nordisk Help Turn $100,000 Into $1 Million in the GLP‑1 Gold Rush? ↗
It would be a near-miracle gain. 
Via The Motley Fool
News headline image
Earnings To Watch: Viatris (VTRS) Reports Q4 Results Tomorrow
Medication company Viatris (NASDAQ:VTRS) will be announcing earnings results this Thursday before market hours. Here’s what to expect. 
Via StockStory
Topics World Trade
News headline image
Collegium Pharmaceutical (COLL) Q4 Earnings: What To Expect
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) will be reporting results this Thursday before market open. Here’s what to expect. 
Via StockStory
Topics World Trade
News headline image
Why Eli Lilly Stock Slumped Today ↗
Investors worried that the company could take quite a revenue hit due to a competitor's move. 
Via The Motley Fool
News headline image
Novo's 'Flashy' Ozempic, Wegovy Price Cuts Unlikely To Impact LLY Stock, Says BofA ↗
Shares of Novo Nordisk and Eli Lilly slipped in afternoon trade after the former announced a reduction in the list prices of its weight loss drugs, Ozempic and Wegovy. 
Via Stocktwits
News headline image
A Tale of Two Titans: Eli Lilly Surges as Novo Nordisk Stumbles in the Weight Loss Price War
The global pharmaceutical landscape underwent a seismic shift today, February 24, 2026, as the two pioneers of the weight loss drug revolution reported vastly different outlooks for the coming year.... 
Via MarketMinute
News headline image
Stock-Split Watch: Is Meta Platforms Next? ↗
Meta is the only "Magnificent Seven" stock that has not had a stock split. 
Via The Motley Fool
TinyGemsBreaks – Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) Appoints Dr. Freda Lewis-Hall to Board and Scientific Advisory Committee Chair
Via Investor Brand Network
News headline image
Hims & Hers Health (HIMS): Decoding the Q4 Earnings Beat vs. the SEC GLP-1 Investigation
As of February 24, 2026, the market narrative surrounding Hims & Hers Health (NYSE: HIMS) has become a stark "tale of two tapes." On one hand, the digital health disruptor recently reported a robust Q4... 
Via Finterra
Topics Earnings Economy Initial Public Offering
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.